scholarly journals Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: the DURAPOP randomised clinical trial

2018 ◽  
Vol 44 (3) ◽  
pp. 300-310 ◽  
Author(s):  
Philippe Montravers ◽  
◽  
Florence Tubach ◽  
Thomas Lescot ◽  
Benoit Veber ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Antibiotic Therapy ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Randomised Clinical Trial ◽  
Abdominal Infection ◽  
Short Course ◽  
Intra Abdominal Infection

Epidemiology and outcomes of source control procedures in critically ill patients with intra-abdominal infection

2019 ◽  
Vol 52 ◽  
pp. 258-264 ◽  
Author(s):  
Kirsten van de Groep ◽  
Tessa L. Verhoeff ◽  
Diana M. Verboom ◽  
Lieuwe D. Bos ◽  
Marcus J. Schultz ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Source Control ◽  
Abdominal Infection ◽  
Control Procedures ◽  
Intra Abdominal Infection

scholarly journals Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension: Protocol for the 65 randomised clinical trial

2020 ◽  
Vol 21 (4) ◽  
pp. 281-282
Author(s):  
Alvin Richards-Belle ◽  
Paul R Mouncey ◽  
Richard D Grieve ◽  
David A Harrison ◽  
M Zia Sadique ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Mean Arterial Pressure ◽  
Arterial Pressure ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Randomised Clinical Trial ◽  
Vasopressor Therapy ◽  
Permissive Hypotension ◽  
Risk Of Death ◽  
South Central

Vasodilatory shock is common in critically ill patients and vasopressors are a mainstay of therapy. A meta-analysis suggested that use of a higher, as opposed to a lower, mean arterial pressure target to guide titration of vasopressor therapy, could be associated with a higher risk of death in older critically ill patients. The 65 trial is a pragmatic, multi-centre, parallel-group, open-label, randomised clinical trial of permissive hypotension (a mean arterial pressure target of 60 -65 mmHg during vasopressor therapy) versus usual care in critically ill patients aged 65 years or over with vasodilatory hypotension. The trial is conducted in 2600 patients from 65 United Kingdom adult, general critical care units. The primary outcome is all-cause mortality at 90 days. An economic evaluation is embedded. The 65 trial received favourable ethical opinion from the South Central - Oxford C Research Ethics Committee and approval from the Health Research Authority. The results will be presented at national and international conferences and published in peer-reviewed medical journals. Trial registration: ISRCTN10580502

scholarly journals Protocol for the pBDG2 Study: Prospective Evaluation of 1.3-β-D-Glucan in the Peritoneal Fluid for the Diagnosis of Intra-Abdominal Candidiasis in Critically Ill Patients

2021 ◽  
Vol 12 (1) ◽  
pp. 196-203
Author(s):  
Emmanuel Novy ◽  
François-Xavier Laithier ◽  
Jeremie Riviere ◽  
Thomas Remen ◽  
Marie-Reine Losser ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Peritoneal Fluid ◽  
Primary Objective ◽  
Current Status ◽  
Control Group ◽  
Abdominal Infection ◽  
Increased Risk ◽  
Intra Abdominal Infection ◽  
Abdominal Candidiasis

Background: The delayed diagnosis of the presence of Candida in severe intra-abdominal infections exposes patients to an increased risk of mortality. The prevalence of intra-abdominal candidiasis (IAC) varies with the type of intra-abdominal infection, the underlying conditions and the presence of risk factors for Candida infection. This study aims to evaluate the interest of the measure of 1.3-β-D-glucan (BDG) in the peritoneal fluid for the early diagnosis of IAC. Methods and analysis: This is a prospective multicenter (n = 5) non-interventional study, focusing on all critically ill patients with an intra-abdominal infection requiring intra-abdominal surgery. The primary objective is to assess the diagnostic performance of the BDG measured in the peritoneal fluid for the early detection of IAC using the Candida culture as the gold standard. The secondary objective is to report the prevalence of IAC in the selected population. This study aims to enroll 200 patients within 48 months. By estimating the prevalence of IAC in the selected population at 30%, 50 patients with IAC (cases) are expected. These 50 IAC cases will be matched with 50 non-IAC patients (as a control group). The peritoneal BDG will be measured a posteriori in all of these 100 selected patients. This article presents the protocol and the current status of the study. Only the prevalence of IAC is reported as preliminary result.

Risk factors for acute kidney injury in critically ill patients with complicated intra-abdominal infection

2017 ◽  
Vol 38 ◽  
pp. 104-108 ◽  
Author(s):  
Alejandro Suarez-de-la-Rica ◽  
Víctor Anillo ◽  
Ana Montero ◽  
Carmen Hernandez-Gancedo ◽  
Araceli Lopez-Tofiño ◽  
...  
Keyword(s):  
Risk Factors ◽  
Acute Kidney Injury ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Kidney Injury ◽  
Abdominal Infection ◽  
Intra Abdominal Infection

scholarly journals Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension: Protocol for the 65 randomised clinical trial

2019 ◽  
pp. 175114371987008 ◽  
Author(s):  
Alvin Richards-Belle ◽  
Paul R Mouncey ◽  
Richard D Grieve ◽  
David A Harrison ◽  
M Zia Sadique ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Mean Arterial Pressure ◽  
Arterial Pressure ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Randomised Clinical Trial ◽  
Vasopressor Therapy ◽  
Permissive Hypotension ◽  
Risk Of Death ◽  
South Central

Vasodilatory shock is common in critically ill patients and vasopressors are a mainstay of therapy. A meta-analysis suggested that use of a higher, as opposed to a lower, mean arterial pressure target to guide titration of vasopressor therapy, could be associated with a higher risk of death in older critically ill patients. The 65 trial is a pragmatic, multi-centre, parallel-group, open-label, randomised clinical trial of permissive hypotension (a mean arterial pressure target of 60–65 mmHg during vasopressor therapy) versus usual care in critically ill patients aged 65 years or over with vasodilatory hypotension. The trial is conducted in 2600 patients from 65 United Kingdom adult, general critical care units. The primary outcome is all-cause mortality at 90 days. An economic evaluation is embedded. The 65 trial received favourable ethical opinion from the South Central – Oxford C Research Ethics Committee and approval from the Health Research Authority. The results will be presented at national and international conferences and published in peer-reviewed medical journals. Trial registration: ISRCTN10580502

Sign in / Sign up

Export Citation Format

Share Document